Clever Leaves Holdings Inc. (NASDAQ:CLVR) has signed a one-year international sales agreement with German- Colombian operator FoliuMed Holdings and its German manufacturing partner, Fidelio Healthcare. With access to three of Clever Leaves’ pharmaceutical grade bulk cannabis extracts, Fidelio will be ramping up production using Clever Leaves’ full spectrum THC crude extract, standardized 20% CBD extract, and CBD isolate.
With high production standards recognized domestically and abroad, including both Good Manufacturing Practices certification from Colombia and European Union Good Manufacturing Practices certification from Europe, Clever Leaves’ Colombian pharmaceutical-grade cannabis will be utilized by Fidelio’s manufacturing and distribution teams to create affordable, orally administered gel capsules for consumption on a prescription basis by customers and patients in Australia, Europe and Latin America. Soft gel capsules are preferred by patients and doctors as they can be dosed more precisely than the market standard cannabis tinctures.
“Leveraging our Colombian operation to build and maintain relationships throughout the cannabinoid and pharmaceutical industry is incredibly important to us,” stated Andrés Fajardo, president and incoming CEO of Clever Leaves in regard to the emerging partnership with FoliuMed. “We’re grateful for the opportunity to expand our international presence by partnering with FoliuMed and Fidelio, bringing Clever Leaves standard of production to a global scale.”
FoliuMed CEO Oliver Zugel commented, “FoliuMed and our manufacturing partner Fidelio are one of the five producers worldwide who manufacture cannabis soft gels for prescription medicines under EU-GMP. We carefully chose Clever Leaves as our preferred raw material supplier for this highly strategic product range. As we are seeing increased customer interest for soft gels, we will expand our range of formulations and are looking forward to work with Clever Leaves in this endeavor.”
Clever Leaves raw materials are shipped to FoliuMed’s German operation near Frankfurt where they are processed into soft gels at Fidelio’s EU-GMP contract manufacturing site and delivered to a leading Australian customer in the first quarter of 2022.
